Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision Targeted Therapy Strategies for Advanced Gastric Cancer
NCT06881017Phase 2Not yet recruiting
- Sponsor
- China Medical University
- Start
- May 2025
- Primary completion
- Aug 2029
- Modality
- Immune Checkpoint Inhibitors, Small Molecules, Antibody-Drug Conjugates (ADCs)
01
Overview
A Phase 2 trial of garetatug rezetecan, trastuzumab rezetecan, retlirafusp alfa, adebrelimab in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by China Medical University. Planned start May 2025; status: not yet recruiting.
02
Drugs
garetatug rezetecantrastuzumab rezetecanretlirafusp alfaadebrelimab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06881017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06881017.